Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology

I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com


DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#CompassPathways #CMPS #MindMed

Similar Posts